trabedersen + artemisinin

**Trabedersen + artemisinin** is a combination drug that merges trabedersen, an antisense oligonucleotide targeting TGF-beta2, with artemisinin, a sesquiterpene lactone used primarily for antimalarial therapy. Trabedersen is researched for its role as an inhibitor of Transforming Growth Factor-beta2 (TGF-beta2), which is implicated in tumor progression and immunosuppression, especially in gliomas and other malignant tumors. Artemisinin, sourced from Artemisia annua, exerts its antimalarial effect by generating free radicals that damage parasite proteins after interaction with iron(II) within the parasite. Artemisinin is noted for its rapid parasite clearance and is recommended by the WHO only as part of artemisinin-based combination therapies for malaria. The mechanistic rationale for combining trabedersen (anticancer/inhibitor of tumor immune evasion) and artemisinin (antimalarial and investigated for some anticancer effects) would be experimental and not supported by standard clinical guidelines or approved therapies as of now. There is no evidence that this particular combination has been clinically developed, approved, or commercially marketed for any indication[1][2][3][4][5][6].

Other names

trabedersenartemisinin